{\rtf1\ansi\ansicpg1252\cocoartf949\cocoasubrtf430
{\fonttbl\f0\froman\fcharset0 TimesNewRomanPSMT;\f1\fswiss\fcharset0 ArialMT;}
{\margl1800\margr1600\margt500\margbl1440}
{\pard\sa900\fs50\f0\i Media Release\par}
Basel, 27 June 2007\line \line \line {\b Preliminary 
results for 
phase III study evaluating CellCept in lupus nephritis} \line \line Aspreva 
Pharmaceuticals 
Corporation and Roche today released preliminary results for a clinical phase III trial comparing CellCept 
(oral mycophenolate mofetil, MMF) to intravenous cyclophosphamide (IVC), which is the current standard 
of care, for inducing treatment response in the induction phase of patients suffering from lupus nephritis.\line \line Although 
response rates were similar in both arms, the trial did not meet its primary objective of demonstrating 
that MMF was superior to IVC in inducing treatment response in this disease. The results relate to the 
induction phase of this study, which was designed to measure treatment response in patients after 24 
weeks of induction therapy with 185 patients in the MMF arm and 185 in the IVC arm. The results indicate 
similar treatment responses were observed, with 56.2% in the MMF arm and 53% in the IVC arm. Additional 
analyses are ongoing to determine the potential for regulatory submission, and Aspreva plans to present 
the final results at an appropriate scientific forum in the future.\line \line Based 
on preliminary analysis, it appears that, in general, the adverse events experienced by patients in 
both arms of the study are consistent with those observed in lupus nephritis patients receiving immunosuppressive 
therapy. Overall incidence of adverse events was comparable in both treatment arms.\line \line {\b About 
Lupus Nephritis} \line Systemic lupus erythematosus (SLE), commonly called lupus, is a 
chronic 
autoimmune disease that causes the body to attack its own tissues and joints. Lupus nephritis, considered 
life threatening but rare, is the most serious manifestation of the disease, which, if left untreated, 
can lead to kidney failure, requiring dialysis and potentially death. It is a complicated disease as 
patients typically fluctuate between periods of intense disease activity when the patient\u8217?s own immune 
system is actively attacking and causing damage in their kidney, interspersed with periods of remission. 
Clinicians estimate that one third to one half of lupus patients have lupus nephritis. There has been 
no new approved treatment for SLE or lupus nephritis in the United States in over forty years. Current 
treatments involve the off-label use of existing cancer drugs such as cyclophosphamide, steroids, and 
other immunosuppressant drugs such as azathioprine.\line \line {\b About 
CellCept} \line CellCept 
is Roche\u8217?s leading immunosuppressant or \u8220?anti-rejection\u8221? drug. It is used in combination with other 
immunosuppressive drugs (cyclosporine and corticosteroids) for the prevention of rejection in patients 
receiving heart, kidney and liver transplants. CellCept was first approved for use in combination therapy 
for the prevention of acute organ rejection in kidney transplantation in 1995 and has since been approved 
worldwide for prevention of organ rejection in adult kidney, heart and liver transplantation. This therapeutic 
success in the prevention of organ rejection in adult kidney, heart and liver transplantation represents 
11 years of clinical experience and patient benefits, including reduced toxicities and prolonged graft 
and patient survival. In July 2003, Aspreva signed a collaboration agreement with Roche for the exclusive 
worldwide rights (excluding Japan) to develop and, upon regulatory approval, commercialise CellCept 
for all autoimmune disease applications. It is important to note that CellCept has not been approved 
by the FDA for the treatment of any autoimmune disease.\line \line {\b About 
Aspreva 
Pharmaceuticals} \line Aspreva is a global pharmaceutical company focused on identifying, 
developing, 
and, upon approval, commercialising evidence-based medicines for patients living with less common diseases. 
Aspreva common stock is traded on the NASDAQ Global Select Market under the trading symbol \u8220?ASPV\u8221? and 
on the Toronto Stock Exchange under the trading symbol "ASV". Learn more at www.aspreva.com (http://www.aspreva.com).\line \line {\b About 
Roche}  \line Headquartered in Basel, Switzerland, Roche is one of the world\u8217?s leading 
research-focused 
healthcare groups in the fields of pharmaceuticals and diagnostics. As the world\u8217?s biggest biotech company 
and an innovator of products and services for the early detection, prevention, diagnosis and treatment 
of diseases, the Group contributes on a broad range of fronts to improving people\u8217?s health and quality 
of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, 
a market leader in virology and active in other major therapeutic areas such as autoimmune diseases, 
inflammation, metabolism and central nervous system. In 2006 sales by the Pharmaceuticals Division totalled 
33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche 
employs roughly 75,000 worldwide and has R&D agreements and strategic alliances with numerous partners, 
including majority ownership interests in Genentech and Chugai. Additional information about the Roche 
Group is available on the Internet at www.roche.com (http://www.roche.com).\line \line {\pard\f0\li0\ri0\sa360\sl360\fs18 All 
trademarks used 
or mentioned in this release are protected by law.\par}
{\pard \par}
{\pard\sb180\f1\fs22 {\b F. Hoffmann-La Roche Ltd}\line 4070 Basel\line Switzerland \par}
{\pard\sb180\f1\fs22 Corporate Communications\line Roche Group Media Relations \par}
{\pard\sb180\f1\fs22 Tel. +41 61 688 88 88\line Fax +41 61 688 27 75\line www.roche.com \par}
}